從全民健保資料分析台灣地區之氣喘治療現況

The Analysis of Asthma Medication in Taiwan, Data from National Health Insurance

方文輝(Wen-Hui Fang) ； 莊明憲(Min-Shen Chaun) ； 陳永煌(Yeong-Hwang Chen) ； 劉紹興(Saou-Hsing Liou) ； 周稚傑(Chih-Chou Chieh)

《中華職業醫學雜誌》 14卷2期 (2007/04) Pp. 77-85

https://doi.org/10.30027/CJOM.200704.0002

摘要

目的：藉著分析全民健保資料之世代追蹤檔，來比較各種劑型之氣喘藥物於不同年齡層的處方率，以期瞭解台灣地區之氣喘病流行病學及氣喘治療現況。材料與方法：本研究資料來自國家衛生研究院所提供之全民健保研究資料，對象為20萬人之抽樣歸戶檔，期間為1997至2004年之資料，病人為接受氣喘病治療之民眾。針對性別與年齡層等自變項，對各種類型的氣喘治療藥物，門診和特約藥局申報處方箋及醫令資料，進行描述性分析。結果:在錠劑方面，乙二型交感神經興奮劑的使用有逐年下降的趨勢，尤其在65歲以上的族群，茶鹼製劑的使用是隨年齡而增加，肥胖細胞穩定劑的使用在19歲以上很少，且有逐年降低的趨勢，12歲以下的使用率也逐年下降，類固醇的使用率除了在6歲以下及13到18歲兩組變化較大外，其餘各組皆在8%到11%之間，白三烯拮抗劑的使用在18歲以下的有逐年上升的趨勢，而且年齡愈低使用的越多；在糖漿製劑方面，乙二型交感神經興奮劑僅6歲以下的族群使用較多且有逐年下降的趨勢；在吸入劑方面，乙二型交感神經興奮劑的吸入劑在13到39歲使用的較多，6歲以下使用較少且所有年齡層的使用率有逐年上升的趨勢，抗膽鹼藥物的吸入劑有隨年齡增加而增加使用的情形，並且有逐年上升的趨勢，類固醇吸入劑的使用有逐年上升的趨勢，其中又以7到39歲的使用最多。

並列摘要

Aim: By analyzing the cohort database of National Health Insurance in Taiwan and exploring the prescription rates of asthma medications for various age groups, we examine trends of asthma treatments in Taiwan.
Material and methods: Systemic sampling cohort database of 200,000 insurers are provided by the National Health Research Institutes (NHRI) for research purpose. Target subjects are those who received asthma treatment between 1997 and 2004. We perform descriptive analysis on types of asthma medications, including those of ambulatory cares and contracted pharmacies, stratified by genders and age groups.
Result: For the tablet forms, the use of β 2-adrenergic agonists decreases year by year, especially for those over 65 years old, while the use of Xanthium derivatives increase. The Mast cell stabilizers are rarely prescribed in those over 19 years old and decrease with time. For those under 12 years old, the utilization also declines by times. The use of corticosteroids varied in 2 groups (below 6 years old and 13~16 years old). The prescription rates in other groups are kept in the range of 8-11%. The use of Leukotrienes antagonists grows for those under18 years old and decreases when patients' ages increase. In the syrup form, β2-adrenergic agonists present in patients under 6 years old and decline with time. In the inhalant form, the use ofβ 2-adrenergic agonists is more prominent in those between 13 and 39 years-old, and increase with time. The use of Anticholinergics increases as patients become old, and increases with time. The use of inhaled corticosteroid grows with time, especially for those from 7 to 39 years old.

並列關鍵字

asthma ； anti-asthmatic medications ； National health insurance